| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 2500% | ₹764.2 0% | 2,600 | ₹0.5 0% | 2500% |
| 5000% | ₹587 0% | 2,800 | ₹2.5 85.18% | 4,0000% |
| - | - | 2,900 | ₹3 -14.28% | 16,7506.34% |
| 5000% | ₹425.95 0% | 2,950 | ₹3.75 -26.47% | 46,2503.35% |
| 7500% | ₹252.85 0% | 3,000 | ₹5.65 -11.71% | 47,5001.06% |
| 5000% | ₹366.8 0% | 3,050 | ₹7.05 -25.78% | 16,7504.68% |
| 2,50042.85% | ₹291.4 7.4% | 3,100 | ₹11.05 -19.92% | 55,250-1.77% |
| 1,2500% | ₹227 0% | 3,150 | ₹16 -20.79% | 16,750-1.47% |
| 22,7500% | ₹206.5 9.98% | 3,200 | ₹25.75 -14.45% | 60,0002.56% |
| 18,7500% | ₹148.3 0% | 3,250 | ₹35.05 -19.61% | 24,250-1.02% |
| 45,250-11.70% | ₹132.1 12.95% | 3,300 | ₹51.95 -14.76% | 68,7507.84% |
| 55,000-5.17% | ₹101 11.29% | 3,350 | ₹72.05 -14.02% | 40,0007.38% |
| 2,68,5008.26% | ₹75.05 12.35% | 3,400 | ₹95.05 -14.86% | 94,250-1.82% |
| 87,000-12.34% | ₹57.05 12.97% | 3,450 | ₹114.75 -19.89% | 8,750-2.77% |
| 2,01,0001.38% | ₹42 15.38% | 3,500 | ₹183.9 0% | 8,0000% |
| 55,750-8.97% | ₹30.15 15.29% | 3,550 | ₹200.4 17.09% | 1,000-20% |
| 2,29,5000.21% | ₹21 13.82% | 3,600 | ₹215 0% | 1,5000% |
| 46,250-7.03% | ₹15.2 11.76% | 3,650 | ₹312.3 0% | 2500% |
| 97,500-3.94% | ₹11.5 10.57% | 3,700 | ₹339.85 0% | 1,5000% |
| 10,00014.28% | ₹8.45 7.64% | 3,750 | ₹406.15 0% | 1,2500% |
| 1,33,75017.06% | ₹6.5 7.43% | 3,800 | ₹430.5 0% | 2500% |
| 24,000-5.88% | ₹4 9.58% | 3,900 | - | - |
The transaction involves around 38.75 lakh shares, priced at ₹1,600 each, being offloaded by JB Chemicals employees who recently converted their stock options.
The acquisition values JB Chemicals at ₹25,689 crore on a fully diluted basis, according to the company’s official announcement.
On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
